August 25, 2010

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Flaherty et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6bfdbfca0359822aa831e https://doi.org/https://doi.org/10.1056/nejmoa1002011

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT1986 · 47,642 citations
2Technology platforms for pharmacogenomic diagnostic assays2004 · 102 citations
3DTIC (NSC-45388) in malignant melanoma: a perspective.1976 · 165 citations
4Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX40322010 · 226 citations
5Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity2008 · 1,347 citations

Preguntar a la IA

Me gusta

Guardar